Pros and cons of antigen-presenting cell targeted tumor vaccines

Journal of Immunology Research

Volumn 2015, Issue , 2015, Pages

  Goyvaerts, Cleo ^a   Breckpot, Karine ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR VACCINE; CANCER VACCINE; TUMOR ANTIGEN;

ANTIGEN PRESENTING CELL; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; DENDRITIC CELL; HUMAN; IMMUNOGENETICS; IMMUNOLOGICAL TOLERANCE; NONHUMAN; PHENOTYPE; REVIEW; VACCINE PRODUCTION; ANIMAL; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; NEOPLASMS;

ANIMALS; ANTIGEN-PRESENTING CELLS; ANTIGENS, NEOPLASM; CANCER VACCINES; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY; NEOPLASMS;

EID: 84947744383     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2015/785634     Document Type: Review

References (200)

1. K. Breckpot, C. Heirman, B. Neyns, and K. Thielemans, "Exploiting dendritic cells for cancer immunotherapy: genetic modification of dendritic cells, " Journal of Gene Medicine, vol. 6, no. 11, pp. 1175-1188, 2004.
2. K. F. Bol, J. Tel, I. J. M. de Vries, and C. G. Figdor, "Naturally circulating dendritic cells to vaccinate cancer patients, "OncoImmunology, vol. 2, no. 3, Article ID e23431, 2013.
3. K. Shortman, M. H. Lahoud, and I. Caminschi, "Improving vaccines by targeting antigens to dendritic cells, " Experimental and Molecular Medicine, vol. 41, no. 2, pp. 61-66, 2009.
4. C. Goyvaerts, K. De Groeve, J. Dingemans et al., "Development of the Nanobody display technology to target lentiviral vectors to antigen-presenting cells, " Gene Therapy, vol. 19, no. 12, pp. 1133-1140, 2012.
5. L. Yang, H. Yang, K. Rideout et al., "Engineered lentivector targeting of dendritic cells for in vivo immunization, " Nature Biotechnology, vol. 26, no. 3, pp. 326-334, 2008.
6. K. Sehgal, K. M. Dhodapkar, and M. V. Dhodapkar, "Targeting human dendritic cells in situ to improve vaccines, " Immunology Letters, vol. 162, no. 1, pp. 59-67, 2014.
7. F. Arce, K. Breckpot, M. Collins, and D. Escors, "Targeting lentiviral vectors for cancer immunotherapy, " Current Cancer Therapy Reviews, vol. 7, no. 4, pp. 248-260, 2011.
8. V. Apostolopoulos, T. Thalhammer, A. G. Tzakos, and L. Stojanovska, "Targeting antigens to dendritic cell receptors for vaccine development, " Journal of Drug Delivery, vol. 2013, Article ID 869718, 22 pages, 2013.
9. N. Bhardwaj, J. W. Young, A. J. Nisanian, J. Baggers, and R. M. Steinman, "Small amounts of superantigen, when presented on dendritic cells, are sufficient to initiate T cell responses, " The Journal of Experimental Medicine, vol. 178, no. 2, pp. 633-642, 1993.
10. R. M. Steinman and Z. A. Cohn, "Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution, " The Journal of Experimental Medicine, vol. 137, no. 5, pp. 1142-1162, 1973.
11. D. Dudziak, A. O. Kamphorst, G. F. Heidkamp et al., "Differential antigen processing by dendritic cell subsets in vivo, " Science, vol. 315, no. 5808, pp. 107-111, 2007.
12. R. S. Allan, J. Waithman, S. Bedoui et al., "Migratory dendritic cells transfer antigen to a lymph node-resident dendritic cell population for efficient CTL priming, " Immunity, vol. 25, no. 1, pp. 153-162, 2006.
13. L. M. Wakim and M. J. Bevan, "Cross-dressed dendritic cells drive memory CD8+ T-cell activation after viral infection, " Nature, vol. 471, no. 7340, pp. 629-632, 2011.
14. C. Coquerelle and M. Moser, "DC subsets in positive and negative regulation of immunity, " Immunological Reviews, vol. 234, no. 1, pp. 317-334, 2010.
15. K. Breckpot, A. Bonehill, and J. L. Aerts, Dendritic Cells: Subtypes, Life Cycle, Activation, Biological Functions and their Exploitation in Cancer Immunotherapy, 2010.
16. A. Mildner and S. Jung, "Development and function of dendritic cell subsets, " Immunity, vol. 40, no. 5, pp. 642-656, 2014.
17. A. K. Palucka, H. Ueno, J. Fay, and J. Banchereau, "Dendritic cells: a critical player in cancer therapy?" Journal of Immunotherapy, vol. 31, no. 9, pp. 793-805, 2008.
18. D. Hawiger, K. Inaba, Y. Dorsett et al., "Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo, " Journal of Experimental Medicine, vol. 194, no. 6, pp. 769-779, 2001.
19. D. K. Banerjee, M. V. Dhodapkar, E. Matayeva, R. M. Steinman, and K. M. Dhodapkar, "Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients, " Blood, vol. 108, no. 8, pp. 2655-2661, 2006.
20. A. L. Blasius and B. Beutler, "Intracellular toll-like receptors, " Immunity, vol. 32, no. 3, pp. 305-315, 2010.
21. T. Kawai and S. Akira, "Toll-like receptor and RIG-1-like receptor signaling, " Annals of the New York Academy of Sciences, vol. 1143, pp. 1-20, 2008.
22. G. M. Barton and J. C. Kagan, "A cell biological view of Toll-like receptor function: regulation through compartmentalization, " Nature Reviews Immunology, vol. 9, no. 8, pp. 535-542, 2009.
23. T. B. H. Geijtenbeek and S. I. Gringhuis, "Signalling through C-type lectin receptors: shaping immune responses, " Nature Reviews Immunology, vol. 9, no. 7, pp. 465-479, 2009.
24. K. Breckpot and D. Escors, "Dendritic cells for active anticancer immunotherapy: targeting activation pathways through genetic modification, " Endocrine, Metabolic and Immune Disorders-Drug Targets, vol. 9, no. 4, pp. 328-343, 2009.
25. N. Onai, A. Obata-Onai, M. A. Schmid, T. Ohteki, D. Jarrossay, and M. G. Manz, "Identification of clonogenic common Flt3+M-CSFR+ plasmacytoid and conventional dendritic cell progenitors in mouse bone marrow, " Nature Immunology, vol. 8, no. 11, pp. 1207-1216, 2007.
26. M. Guilliams, F. Ginhoux, C. Jakubzick et al., "Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny, " Nature Reviews Immunology, vol. 14, no. 8, pp. 571-578, 2014.
27. H. S. Ghosh, B. Cisse, A. Bunin, K. L. Lewis, and B. Reizis, "Continuous expression of the transcription factor e2-2 maintains the cell fate of mature plasmacytoid dendritic cells, " Immunity, vol. 33, no. 6, pp. 905-916, 2010.
28. A. Schlitzer and F. Ginhoux, "Organization of the mouse and human DC network, " Current Opinion in Immunology, vol. 26, pp. 90-99, 2014.
29. C.-A. Dutertre, L.-F. Wang, and F. Ginhoux, "Aligning bona fide dendritic cell populations across species, " Cellular Immunology, vol. 291, no. 1-2, pp. 3-10, 2014.
30. G. T. Belz and S. L. Nutt, "Transcriptional programming of the dendritic cell network, " Nature Reviews Immunology, vol. 12, no. 2, pp. 101-113, 2012.
31. L. Chorro, A. Sarde, M. Li et al., "Langerhans cell (LC) proliferation mediates neonatal development, homeostasis, and inflammation-associated expansion of the epidermal LC network, " The Journal of Experimental Medicine, vol. 206, no. 13, pp. 3089-3100, 2009.
32. F. P. Siegal, N. Kadowaki, M. Shodell et al., "The nature of the principal type 1 interferon-producing cells in human blood, " Science, vol. 284, no. 5421, pp. 1835-1837, 1999.
33. C. Cheong, I. Matos, J.-H. Choi et al., "Microbial stimulation fully differentiates monocytes to DC-SIGN/CD209+ dendritic cells for immune T cell areas, " Cell, vol. 143, no. 3, pp. 416-429, 2010.
34. E. Klechevsky and J. Banchereau, "Human dendritic cells subsets as targets and vectors for therapy, " Annals of the New York Academy of Sciences, vol. 1284, no. 1, pp. 24-30, 2013.
35. M. Haniffa, A. Shin, V. Bigley et al., "Human tissues contain CD141hi cross-presenting dendritic cells with functional homology to mouse CD103+ nonlymphoid dendritic cells, " Immunity, vol. 37, no. 1, pp. 60-73, 2012.
36. K. Shortman and W. R. Heath, "The CD8+ dendritic cell subset, " Immunological Reviews, vol. 234, no. 1, pp. 18-31, 2010.
37. M. Semmrich, M. Plantinga, M. Svensson-Frej et al., "Directed antigen targeting in vivo identifies a role for CD103+ dendritic cells in both tolerogenic and immunogenic T-cell responses, " Mucosal Immunology, vol. 5, no. 2, pp. 150-160, 2012.
38. S. Meixlsperger, C. S. Leung, P. C. Ramer et al., "CD141+ dendritic cells produce prominent amounts of IFN-α after dsRNA recognition and can be targeted via DEC-205 in humanized mice, " Blood, vol. 121, no. 25, pp. 5034-5044, 2013.
39. M. L. Broz, M. Binnewies, B. Boldajipour et al., "Dissecting the tumor myeloid compartment reveals rare activating antigenpresenting cells critical for T cell immunity, " Cancer Cell, vol. 26, no. 5, pp. 638-652, 2014.
40. W. Kastenmuller, K. Kastenmuller, C. Kurts, and R. A. Seder, "Dendritic cell-targeted vaccines-hope or hype?" Nature Reviews Immunology, vol. 14, no. 10, pp. 705-711, 2014.
41. K. Palucka, J. Banchereau, and I. Mellman, "Designing vaccines based on biology of human dendritic cell subsets, " Immunity, vol. 33, no. 4, pp. 464-478, 2010.
42. H. Hochrein, M. O'Keeffe, and H. Wagner, "Human and mouse plasmacytoid dendritic cells, " Human Immunology, vol. 63, no. 12, pp. 1103-1110, 2002.
43. J. Tel, E. H. J. G. Aarntzen, T. Baba, and et al, "Natural human plasmacytoid dendritic cells induce antigen-specific Tcell responses in melanoma patients, " Cancer Research, vol. 73, no. 3, pp. 1063-1075, 2013.
44. K. Palucka, H. Ueno, L. Roberts, J. Fay, and J. Banchereau, "Dendritic cell subsets as vectors and targets for improved cancer therapy, " Current Topics In Microbiology and Immunology, vol. 344, pp. 173-192, 2011.
45. C. Goyvaerts, D. G. Kurt, S. Van Lint et al., "Immunogenicity of targeted lentivectors, " Oncotarget, vol. 5, no. 3, pp. 704-715, 2014.
46. S. Van Lint, D. Renmans, K. Broos et al., "The ReNAissanCe of mRNA-based cancer therapy, " Expert ReviewofVaccines, vol. 14, no. 2, pp. 235-251, 2015.
47. Z. Amoozgar and M. S. Goldberg, "Targeting myeloid cells using nanoparticles to improve cancer immunotherapy, " Advanced Drug Delivery Reviews, 2014.
48. H. Dewitte, R. Verbeke, K. Breckpot, S. C. De Smedt, and I. Lentacker, "Nanoparticle design to induce tumor immunity and challenge the suppressive tumor microenvironment, " Nano Today, vol. 9, no. 6, pp. 743-758, 2014.
49. M. Dullaers, S. Van Meirvenne, C. Heirman et al., "Induction of effective therapeutic antitumor immunity by direct in vivo administration of lentiviral vectors, " Gene Therapy, vol. 13, no. 7, pp. 630-640, 2006.
50. L. Chapatte, S. Colombetti, J.-C. Cerottini, and F. Levy, "Efficient induction of tumor antigen-specific CD8+ memory T cells by recombinant lentivectors, " Cancer Research, vol. 66, no. 2, pp. 1155-1160, 2006.
51. S. Rusakiewicz, M. Dosset, K. Mollier et al., "Immunogenicity of a recombinant lentiviral vector carrying human telomerase tumor antigen in HLA-B∗0702 transgenic mice, " Vaccine, vol. 28, no. 38, pp. 6374-6381, 2010.
52. S. Van Lint, C. Goyvaerts, S. Maenhout et al., "Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy, " Cancer Research, vol. 72, no. 7, pp. 1661-1671, 2012.
53. I. C. Kourtis, S. Hirosue, A. de Titta et al., "Peripherally administered nanoparticles target monocytic myeloid cells, secondary lymphoid organs and tumors in mice, " PLoS ONE, vol. 8, no. 4, Article IDe61646, 2013.
54. C. Wang, P. Liu, Y. Zhuang et al., "Lymphatic-targeted cationic liposomes: a robust vaccine adjuvant for promoting long-term immunological memory, " Vaccine, vol. 32, no. 42, pp. 5475-5483, 2014.
55. N. K. Kunda, I. M. Alfagih, S. R. Dennison et al., "Bovine serum albumin adsorbed PGA-co-PDL nanocarriers for vaccine delivery via dry powder inhalation, " Pharmaceutical Research, vol. 32, no. 4, pp. 1341-1353, 2015.
56. S. N. Thomas, E. Vokali, A. W. Lund, J. A. Hubbell, and M. A. Swartz, "Targeting the tumor-draining lymph node with adjuvanted nanoparticles reshapes the anti-tumor immune response, " Biomaterials, vol. 35, no. 2, pp. 814-824, 2014.
57. L. Jeanbart, M. Ballester, A. de Titta et al., "Enhancing efficacy of anticancer vaccines by targeted delivery to tumor-draining lymph nodes, " Cancer Immunology Research, vol. 2, no. 5, pp. 436-447, 2014.
58. H. Dewitte, S. Van Lint, C. Heirman et al., "Thepotential of antigen and TriMix sonoporation using mRNA-loaded microbubbles for ultrasound-triggered cancer immunotherapy, " Journal of Controlled Release, vol. 194, pp. 28-36, 2014.
59. M. Zaric, O. Lyubomska, C. Poux et al., "Dissolving microneedle delivery of nanoparticle-encapsulated antigen elicits efficient cross-priming and Th1 immune responses by murine langerhans cells, " Journal of Investigative Dermatology, vol. 135, no. 2, pp. 425-434, 2014.
60. M. Zaric, O. Lyubomska, O. Touzelet et al., "Skin dendritic cell targeting via microneedle arrays laden with antigenencapsulated poly-d, l-lactide-co-glycolide nanoparticles induces efficient antitumor and antiviral immune responses, " ACS Nano, vol. 7, no. 3, pp. 2042-2055, 2013.
61. K. Van der Jeught, L. Bialkowski, L. Daszkiewicz et al., "Targeting the tumor microenvironment to enhance antitumor immune responses, " Oncotarget, vol. 6, no. 3, pp. 1359-1381, 2015.
62. S. A. Rosenberg, R. M. Sherry, K. E. Morton et al., "Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma, "The Journal of Immunology, vol. 175, no. 9, pp. 6169-6176, 2005.
63. A. A. Keskinov and M. R. Shurin, "Myeloid regulatory cells in tumor spreading and metastasis, " Immunobiology, vol. 220, pp. 236-242, 2014.
64. J. M. T. Janco, P. Lamichhane, L. Karyampudi, and K. L. Knutson, "Tumor-infiltrating dendritic cells in cancer pathogenesis, " The Journal of Immunology, vol. 194, no. 7, pp. 2985-2991, 2015.
65. S. Kim, G. J. Kim, H. Miyoshi et al., "Efficiency of the elongation factor-1alpha promoter in mammalian embryonic stem cells using lentiviral gene delivery systems, " StemCells and Development, vol. 16, no. 4, pp. 537-545, 2007.
66. D. E. Gilham, M. Lie-A-Ling, N. Taylor, and R. E. Hawkins, "Cytokine stimulation and the choice of promoter are critical factors for the efficient transduction ofmouse T cellswithHIV-1 vectors, "TheJournal ofGeneMedicine, vol. 12, no. 2, pp. 129-136, 2010.
67. M. Li, N. Husic, Y. Lin et al., "Optimal promoter usage for lentiviral vector-mediated transduction of cultured central nervous system cells, " Journal of NeuroscienceMethods, vol. 189, no. 1, pp. 56-64, 2010.
68. B. H. Liu, X. Wang, Y. X. Ma, and S. Wang, "CMV enhancer/ human PDGF-β promoter for neuron-specific transgene expression, " GeneTherapy, vol. 11, no. 1, pp. 52-60, 2004.
69. S. Stein, M. G. Ott, S. Schultze-Strasser et al., "Genomic instability andmyelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease, " Nature Medicine, vol. 16, no. 2, pp. 198-204, 2010.
70. F. Di Nunzio, G. Maruggi, S. Ferrari et al., "Correction of laminin-5 deficiency in human epidermal stem cells by transcriptionally targeted lentiviral vectors, "MolecularTherapy, vol. 16, no. 12, pp. 1977-1985, 2008.
71. J. Cao, K. Sodhi, K. Inoue et al., "Lentiviral-human heme oxygenase targeting endothelium improved vascular function in angiotensin II animal model of hypertension, " Human Gene Therapy, vol. 22, no. 3, pp. 271-282, 2011.
72. L. Lopes, M. Dewannieux, U. Gileadi et al., "Immunization with a lentivector that targets tumor antigen expression to dendritic cells induces potent CD8+ and CD4+ T-cell responses, " Journal of Virology, vol. 82, no. 1, pp. 86-95, 2008.
73. Y. Cui, J. Golob, E. Kelleher, Z. Ye, D. Pardoll, and L. Cheng, "Targeting transgene expression to antigen-presenting cells derived from lentivirus-transduced engrafting human hematopoietic stem/progenitor cells, " Blood, vol. 99, no. 2, pp. 399-408, 2002.
74. M. Pincha, G. Salguero, D. Wedekind et al., "Lentiviral vectors for induction of self-differentiation and conditional ablation of dendritic cells, " GeneTherapy, vol. 18, no. 8, pp. 750-764, 2011.
75. V. Moulin, M. E. Morgan, D. Eleveld-Trancikova et al., "Targeting dendritic cells with antigen via dendritic cell-associated promoters, " Cancer Gene Therapy, vol. 19, no. 5, pp. 303-311, 2012.
76. C. Dresch, S. L. Edelmann, P. Marconi, and T. Brocker, "Lentiviral-mediated transcriptional targeting of dendritic cells for induction of T cell tolerance in vivo, " Journal of Immunology, vol. 181, no. 7, pp. 4495-4506, 2008.
77. B. De Andrade Pereira, C. Fraefel, M. Hilbe, M. Ackermann, and C. Dresch, "Transcriptional targeting ofDCs with lentiviral vectors induces antigen-specific tolerance in a mouse model of multiple sclerosis, " Gene Therapy, vol. 20, no. 5, pp. 556-566, 2013.
78. M. De Palma, E. Montini, F. R. Santoni De Sio et al., "Promoter trapping reveals significant differences in integration site selection between MLV and HIV vectors in primary hematopoietic cells, " Blood, vol. 105, no. 6, pp. 2307-2315, 2005.
79. A. Schambach, D. Zychlinski, B. Ehrnstroem, and C. Baum, "Biosafety features of lentiviral vectors, " Human GeneTherapy, vol. 24, no. 2, pp. 132-142, 2013.
80. B. Barrilleaux and P. Knoepfler, "Transduction of human cells with polymer-complexed ecotropic lentivirus for enhanced biosafety, " Journal of Visualized Experiments, no. 53, 2011.
81. C. G. Park, "Vaccine strategies utilizing C-type lectin receptors on dendritic cells in vivo, " Clinical and Experimental Vaccine Research, vol. 3, no. 2, pp. 149-154, 2014.
82. I. Streng-Ouwehand, W. W. J. Unger, and Y. Van Kooyk, "Ctype lectin receptors for tumor eradication: future directions, " Cancers, vol. 3, no. 3, pp. 3169-3188, 2011.
83. C. L. Van Broekhoven, C. R. Parish, C. Demangel, W. J. Britton, and J. G. Altin, "Targeting dendritic cells with antigencontaining liposomes: a highly effective procedure for induction of antitumor immunity and for tumor immunotherapy, " Cancer Research, vol. 64, no. 12, pp. 4357-4365, 2004.
84. Y. Liu, A. Tai, K.-I. Joo, and P. Wang, "Visualization of DCSIGN- mediated entry pathway of engineered lentiviral vectors in target cells, " PLoS ONE, vol. 8, no. 6, Article ID e67400, 2013.
85. D. Li, G. Romain, A.-L. Flamar et al., "Targeting self- and foreign antigens to dendritic cells via DC-ASGPR generates IL-10- producing suppressive CD4+ T cells, " Journal of Experimental Medicine, vol. 209, no. 1, pp. 109-121, 2012.
86. A. Bachem, E. Hartung, S. Guttler et al., "Expression of XCR1 characterizes the Batf3-dependent lineage of dendritic cells capable of antigen cross-presentation, " Frontiers in Immunology, vol. 3, article 214, 2012.
87. A. Bachem, S. Guttler, E. Hartung et al., "Superior antigen cross-presentation and XCR1 expression define human CD11c+CD141+ cells as homologues of mouse CD8+ dendritic cells, " Journal of ExperimentalMedicine, vol. 207, no. 6, pp. 1273-1281, 2010.
88. K. M. Tullett, M. H. Lahoud, and K. J. Radford, "Harnessing human cross-presenting CLEC9A+XCR1+ dendritic cells for immunotherapy, " Frontiers in Immunology, vol. 5, article 239, 2014.
89. D. V. Schaffer, J. T. Koerber, and K. Lim, "Molecular engineering of viral gene delivery vehicles, " Annual Review of Biomedical Engineering, vol. 10, no. 1, pp. 169-194, 2008.
90. M. Sioud, G. Skorstad, A. Mobergslien, and S. Sboe-Larssen, "A novel peptide carrier for efficient targeting of antigens and nucleic acids to dendritic cells, " The FASEB Journal, vol. 27, no. 8, pp. 3272-3283, 2013.
91. G. H. Guibinga, F. L. Hall, E. M. Gordon, E. Ruoslahti, and T. Friedmann, "Ligand-modified vesicular stomatitis virus glycoprotein displays a temperature-sensitive intracellular trafficking and virus assembly phenotype, "MolecularTherapy, vol. 9, no. 1, pp. 76-84, 2004.
92. D. Lavillette, S. J. Russell, and F.-L. Cosset, "Retargeting gene delivery using surface-engineered retroviral vector particles, " Current Opinion in Biotechnology, vol. 12, no. 5, pp. 461-466, 2001.
93. M. Katane, E. Takao, Y. Kubo, R. Fujita, and H. Amanuma, "Factors affecting the direct targeting of murine leukemia virus vectors containing peptide ligands in the envelope protein, " EMBO Reports, vol. 3, no. 9, pp. 899-904, 2002.
94. G. Karavanas, M. Marin, E. Bachrach, A. G. Papavassiliou, and M. Piechaczyk, "The insertion of an anti-MHC I ScFv into the N-terminus of an ecotropicMLV glycoprotein does not alter its fusiogenic potential onmurine cells, " Virus Research, vol. 83, no. 1-2, pp. 57-69, 2002.
95. B. C. Wengerter, J. A. Katakowski, J. M. Rosenberg et al., "Aptamer-targeted antigen delivery, "MolecularTherapy, vol. 22, no. 7, pp. 1375-1387, 2014.
96. R. C. Munch, M. D. Muhlebach, T. Schaser et al., "DARPins: an efficient targeting domain for lentiviral vectors, " Molecular Therapy, vol. 19, no. 4, pp. 686-693, 2011.
97. C. Hamers-Casterman, T. Atarhouch, S. Muyldermans et al., "Naturally occurring antibodies devoid of light chains, " Nature, vol. 363, no. 6428, pp. 446-448, 1993.
98. S. Muyldermans, "Nanobodies: natural single-domain antibodies, " Annual Review of Biochemistry, vol. 82, no. 1, pp. 775-797, 2013.
99. I. Vaneycken, M. Dhuyvetter, S. Hernot et al., "Immunoimaging using nanobodies, " Current Opinion in Biotechnology, vol. 22, no. 6, pp. 877-881, 2011.
100. J. De Vos, N. Devoogdt, T. Lahoutte, and S. Muyldermans, "Camelid single-domain antibody-fragment engineering for (pre)clinical in vivo molecular imaging applications: adjusting the bullet to its target, " Expert Opinion on Biological Therapy, vol. 13, no. 8, pp. 1149-1160, 2013.
101. K. Movahedi, S. Schoonooghe, D. Laoui et al., "Nanobodybased targeting of the macrophage mannose receptor for effective in vivo imaging of tumor-associated macrophages, " Cancer Research, vol. 72, no. 16, pp. 4165-4177, 2012.
102. K. De Groeve, N. Deschacht, C. De Koninck et al., "Nanobodies as tools for in vivo imaging of specific immune cell types, " Journal of Nuclear Medicine, vol. 51, no. 5, pp. 782-789, 2010.
103. L. Xiao, K.-I. Joo, M. Lim, and P. Wang, "Dendritic cell-directed vaccination with a lentivector encoding PSCA for prostate cancer in mice, " PloS ONE, vol. 7, no. 11, Article IDe48866, 2012.
104. B. Hu, B. Dai, and P. Wang, "Vaccines delivered by integrationdeficient lentiviral vectors targeting dendritic cells induces strong antigen-specific immunity, " Vaccine, vol. 28, no. 41, pp. 6675-6683, 2010.
105. B. Dai, L. Yang, H. Yang, B. Hu, D. Baltimore, and P. Wang, "HIV-1 Gag-specific immunity induced by a lentivector-based vaccine directed to dendritic cells, " Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 48, pp. 20382-20387, 2009.
106. V. Karanikas, L.-A. Hwang, J. Pearson et al., "Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein, " The Journal of Clinical Investigation, vol. 100, no. 11, pp. 2783-2792, 1997.
107. M. A. Croyle, S. M. Callahan, A. Auricchio et al., "PEGylation of a vesicular stomatitis virus G pseudotyped lentivirus vector prevents inactivation in serum, " Journal of Virology, vol. 78, no. 2, pp. 912-921, 2004.
108. J.-C. Zeng, Z. Zhang, T.-Y. Li et al., "Assessing the role of IL-35 in colorectal cancer progression and prognosis, " International Journal of Clinical and Experimental Pathology, vol. 6, no. 9, pp. 1806-1816, 2013.
109. C. J. Buchholz, L. J. Duerner, S. Funke, and I. C. Schneider, "Retroviral display and high throughput screening, " Combinatorial Chemistry and High Throughput Screening, vol. 11, no. 2, pp. 99-110, 2008.
110. C. Metzner, F. Kochan, and J. A. Dangerfield, "Postexit surface engineering of retroviral/lentiviral vectors, " BioMed Research International, vol. 2013, Article ID 253521, 8 pages, 2013.
111. C. Goyvaerts, J. Dingemans, K. De Groeve et al., "Targeting of human antigen-presenting cell subsets, " Journal of Virology, vol. 87, no. 20, pp. 11304-11308, 2013.
112. S. Cire, S. Da Rocha, R. Yao et al., "Immunization of mice with lentiviral vectors targeted to MHC class II+ cells is due to preferential transduction of dendritic cells in vivo, " PLoS ONE, vol. 9, no. 7, Article ID e101644, 2014.
113. G. Dadaglio, C. Fayolle, X. Zhang et al., "Antigen targeting to CD11b+ dendritic cells in association with TLR4/TRIF signaling promotes strong CD8+ T cell responses, " Journal of Immunology, vol. 193, no. 4, pp. 1787-1798, 2014.
114. M. M. Seavey, Z.-K. Pan, P. C. Maciag et al., "A novel human Her-2/neu chimeric molecule expressed by listeria monocytogenes can elicit potent HLA-A2 restricted CD8-positive T cell responses and impact the growth and spread of Her-2/neupositive breast tumors, " Clinical Cancer Research, vol. 15, no. 3, pp. 924-932, 2009.
115. D. T. Le, T. W. Dubenksy Jr., and D. G. Brockstedt, "Clinical development of listeria monocytogenes-based immunotherapies, " Seminars in Oncology, vol. 39, no. 3, pp. 311-322, 2012.
116. C. S. Leung, M. A. Maurer, S. Meixlsperger et al., "Robust Tcell stimulation by Epstein-Barr virus-transformed B cells after antigen targeting to DEC-205, " Blood, vol. 121, no. 9, pp. 1584-1594, 2013.
117. M. D. Joshi, W. J. Unger, G. Storm, Y. Van Kooyk, and E. Mastrobattista, "Targeting tumor antigens to dendritic cells using particulate carriers, " Journal of Controlled Release, vol. 161, no. 1, pp. 25-37, 2012.
118. M. Maglinao, M. Eriksson, M. K. Schlegel et al., "A platform to screen for C-type lectin receptor-binding carbohydrates and their potential for cell-specific targeting and immune modulation, " Journal of Controlled Release, vol. 175, no. 1, pp. 36-42, 2014.
119. M. Kreutz, P. J. Tacken, and C. G. Figdor, "Targeting dendritic cells-why bother?" Blood, vol. 121, no. 15, pp. 2836-2844, 2013.
120. M. Kreutz, B. Giquel, Q. Hu et al., "Antibody-antigen-adjuvant conjugates enable co-delivery of antigen and adjuvant to dendritic cells in cis but only have partial targeting specificity, " PLoS ONE, vol. 7, no. 7, Article ID e40208, 2012.
121. L. J. Thomann-Harwood, P. Kaeuper, N. Rossi, P. Milona, B. Herrmann, and K. C. McCullough, "Nanogel vaccines targeting dendritic cells: contributions of the surface decoration and vaccine cargo on cell targeting and activation, " Journal of Controlled Release, vol. 166, no. 2, pp. 95-105, 2013.
122. L. E. Ruff, E. A. Mahmoud, J. Sankaranarayanan et al., "Antigenloaded pH-sensitive hydrogel microparticles are taken up by dendritic cells with no requirement for targeting antibodies, " Integrative Biology, vol. 5, no. 1, pp. 195-203, 2013.
123. A. Reuter, S. E. Panozza, C. Macri et al., "Criteria for dendritic cell receptor selection for efficient antibody-targeted vaccination, " The Journal of Immunology, vol. 194, no. 6, pp. 2696-2705, 2015.
124. L.-Z. He, J. Weidlick, C. Sisson, H. C. Marsh, and T. Keler, "Toll-like receptor agonists shape the immune responses to a mannose receptor-targeted cancer vaccine, " Cellular and Molecular Immunology, 2014.
125. J.-S. Thomann, B. Heurtault, S. Weidner et al., "Antitumor activity of liposomal ErbB2/HER2 epitope peptide-based vaccine constructs incorporating TLR agonists and mannose receptor targeting, " Biomaterials, vol. 32, no. 20, pp. 4574-4583, 2011.
126. A. C. Armstrong and D. E. Gilham, "Targeting breast cancer vaccines to dendritic cells: improved immunological responses with less protein?" Breast Cancer Research, vol. 14, article 106, 2012.
127. M. Tenbusch, G. Nchinda, M. S. G. Bonsmann, V. Temchura, and K. Uberla, "Targeting the antigen encoded by adenoviral vectors to the DEC205 receptor modulates the cellular and humoral immune response, " International Immunology, vol. 25, no. 4, pp. 247-258, 2013.
128. I. Caminschi, E. Maraskovsky, and W. R. Heath, "Targeting dendritic cells in vivo for cancer therapy, " Frontiers in Immunology, vol. 3, article 13, 2012.
129. S. Basta and A. Alatery, "The cross-priming pathway: a portrait of an intricate immune system, " Scandinavian Journal of Immunology, vol. 65, no. 4, pp. 311-319, 2007.
130. P. J. Tacken, I. S. Zeelenberg, L. J. Cruz et al., "Targeted delivery of TLR ligands to human and mouse dendritic cells strongly enhances adjuvanticity, " Blood, vol. 118, no. 26, pp. 6836-6844, 2011.
131. L. C. Bonifaz, D. P. Bonnyay, A. Charalambous et al., "In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination, " Journal of Experimental Medicine, vol. 199, no. 6, pp. 815-824, 2004.
132. J. Idoyaga, A. Lubkin, C. Fiorese et al., "Comparable T helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8dendritic cellswithin antibodies to Langerin, DEC205, and Clec9A, " Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 6, pp. 2384-2389, 2011.
133. J. Tel, S. P. Sittig, R. A. M. Blom et al., "Targeting uptake receptors on human plasmacytoid dendritic cells triggers antigen cross-presentation and robust type I IFN secretion, " The Journal of Immunology, vol. 191, no. 10, pp. 5005-5012, 2013.
134. K. J. Radford, K. M. Tullett, and M. H. Lahoud, "Dendritic cells and cancer immunotherapy, " Current Opinion in Immunology, vol. 27, no. 1, pp. 26-32, 2014.
135. C. P. Chappell, N. V. Giltiay, C. Dresch, and E. A. Clark, "Controlling immune responses by targeting antigens to dendritic cell subsets and B cells, " International Immunology, vol. 26, no. 1, pp. 3-11, 2014.
136. R. Maldonado-Lopez, T. De Smedt, P. Michel et al., "CD8α+ and CD8α? subclasses of dendritic cells direct the development of distinct T helper cells in vivo, " Journal of ExperimentalMedicine, vol. 189, no. 3, pp. 587-592, 1999.
137. C.-C. Chu, N. Ali, P. Karagiannis et al., "Resident CD141 (BDCA3)+ dendritic cells in human skin produce IL-10 and induce regulatory T cells that suppress skin inflammation, " Journal of Experimental Medicine, vol. 209, no. 5, pp. 935-945, 2012.
138. D. Sancho, D. Mourao-Sa, O. P. Joffre et al., "Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin, " Journal of Clinical Investigation, vol. 118, no. 6, pp. 2098-2110, 2008.
139. O. P. Joffre, D. Sancho, S. Zelenay, A. M. Keller, and C. Reis e Sousa, "Efficient and versatile manipulation of the peripheral CD4+ T-cell compartment by antigen targeting to DNGR-1/CLEC9A, " European Journal of Immunology, vol. 40, no. 5, pp. 1255-1265, 2010.
140. V. Apostolopoulos, G. A. Pietersz, A. Tsibanis et al., "Dendritic cell immunotherapy: clinical outcomes, " Clinical and Translational Immunology, vol. 3, no. 7, article e21, 2014.
141. K. Kobiyama, T. Aoshi, H. Narita et al., "Nonagonistic Dectin-1 ligand transforms CpG into a multitask nanoparticulate TLR9 agonist, " Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 8, pp. 3086-3091, 2014.
142. L. Cohn and L. Delamarre, "Dendritic cell-targeted vaccines, " Frontiers in Immunology, vol. 5, article 255, 2014.
143. K. Kastenmuller, U. Wille-Reece, R. W. B. Lindsay et al., "Protective T cell immunity in mice following protein-TLR7/8 agonistconjugate immunization requires aggregation, type I IFN, and multiple DC subsets, " The Journal of Clinical Investigation, vol. 121, no. 5, pp. 1782-1796, 2011.
144. K. Sehgal, R. Ragheb, T. M. Fahmy, M. V. Dhodapkar, and K. M. Dhodapkar, "Nanoparticle-mediated combinatorial targeting of multiple human dendritic cell (DC) subsets leads to enhanced T cell activation via IL-15-dependent DC crosstalk, " Journal of Immunology, vol. 193, no. 5, pp. 2297-2305, 2014.
145. F. Wimmers, G. Schreibelt, A. E. Skold, C. G. Figdor, and I. J. M. De Vries, "Paradigm shift in dendritic cell-based immunotherapy: fromin vitro generatedmonocyte-derivedDCs to naturally circulating DC subsets, " Frontiers in Immunology, vol. 5, article 165, 2014.
146. G. Grodeland, S. Mjaaland, G. Tunheim, A. B. Fredriksen, and B. Bogen, "The specificity of targeted vaccines for APC surface molecules influences the immune response phenotype, " PLoS ONE, vol. 8, no. 11, Article ID e80008, 2013.
147. E. Macho-Fernandez, L. J. Cruz, R. Ghinnagow et al., "Targeted delivery of α-galactosylceramide to CD8α+ dendritic cells optimizes type I NKT cell-based antitumor responses, " Journal of Immunology, vol. 193, no. 2, pp. 961-969, 2014.
148. B. Wang, "Targeting dendritic cells in situ for breast cancer immunotherapy, " OncoImmunology, vol. 1, no. 8, pp. 1398-1400, 2012.
149. B. Wang, N. Zaidi, L.-Z. He et al., "Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice, " Breast Cancer Research, vol. 14, no. 2, articleR39, 2012.
150. B. Wang, J. M. Y. Kuroiwa, L.-Z. He, A. Charalambous, T. Keler, and R. M. Steinman, "The human cancer antigen mesothelin is more efficiently presented to the mouse immune system when targeted to the DEC-205/CD205 receptor on dendritic cells, " Annals of the New York Academy of Sciences, vol. 1174, pp. 6-17, 2009.
151. R. Sartorius, C. Bettua, L. D'Apice et al., "Vaccination with filamentous bacteriophages targeting DEC-205 induces DC maturation and potent anti-tumor T-cell responses in the absence of adjuvants, " European Journal of Immunology, vol. 41, no. 9, pp. 2573-2584, 2011.
152. K. Mahnke, Y. Qian, S. Fondel, J. Brueck, C. Becker, and A. H. Enk, "Targeting of antigens to activated dendritic cells in vivo cures metastatic melanoma in mice, " Cancer Research, vol. 65, no. 15, pp. 7007-7012, 2005.
153. J. Cao, Y. Jin, W. Li et al., "DNA vaccines targeting the encoded antigens to dendritic cells induce potent antitumor immunity in mice, " BMC Immunology, vol. 14, article 39, 2013.
154. M. V. Dhodapkar, M. Sznol, B. Zhao et al., "Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205, " Science Translational Medicine, vol. 6, no. 232, Article ID 232ra51, 2014.
155. J. M. Silva, E. Zupancic, G. Vandermeulen et al., "In vivo delivery of peptides and Toll-like receptor ligands by mannosefunctionalized polymeric nanoparticles induces prophylactic and therapeutic anti-tumor immune responses in a melanoma model, " Journal of Controlled Release, vol. 198, pp. 91-103, 2015.
156. L.-Z. He, A. Crocker, J. Lee et al., "Antigenic targeting of the human mannose receptor induces tumor immunity, " Journal of Immunology, vol. 178, no. 10, pp. 6259-6267, 2007.
157. V. Apostolopoulos, G. A. Pietersz, and I. F. C. McKenzie, "Cellmediated immune responses to MUC1 fusion protein coupled to mannan, " Vaccine, vol. 14, no. 9, pp. 930-938, 1996.
158. K.-C. Sheng, M. Kalkanidis, D. S. Pouniotis et al., "Delivery of antigen using a novel mannosylated dendrimer potentiates immunogenicity in vitro and in vivo, " European Journal of Immunology, vol. 38, no. 2, pp. 424-436, 2008.
159. Z. Cui, S.-J. Han, and L. Huang, "Coating of mannan on LPD particles containingHPV E7 peptide significantly enhances immunity against HPV-positive tumor, " Pharmaceutical Research, vol. 21, no. 6, pp. 1018-1025, 2004.
160. F. Perche, T. Benvegnu, M. Berchel et al., "Enhancement of dendritic cells transfection in vivo and of vaccination against B16F10 melanoma with mannosylated histidylated lipopolyplexes loaded with tumor antigen messenger RNA, " Nanomedicine: Nanotechnology, Biology, and Medicine, vol. 7, no. 4, pp. 445-453, 2011.
161. M. Mockey, E. Bourseau, V. Chandrashekhar et al., "mRNAbased cancer vaccine: prevention of B16 melanoma progression and metastasis by systemic injection ofMART1 mRNA histidylated lipopolyplexes, " Cancer Gene Therapy, vol. 14, no. 9, pp. 802-814, 2007.
162. H. Shiku, L. Wang, Y. Ikuta et al., "Development of a cancer vaccine: peptides, proteins, and DNA, " Cancer Chemotherapy and Pharmacology, vol. 46, supplement, pp. S77-S82, 2000.
163. P. M. Moyle, C. Olive, M.-F. Ho et al., "Toward the development of prophylactic and therapeutic human papillomavirus type-16 lipopeptide vaccines, " Journal of Medicinal Chemistry, vol. 50, no. 19, pp. 4721-4727, 2007.
164. M. A. Morse, R. Chapman, J. Powderly et al., "Phase I study utilizing a novel antigen-presenting cell-targeted vaccine with toll-like receptor stimulation to induce immunity to selfantigens in cancer patients, " Clinical Cancer Research, vol. 17, no. 14, pp. 4844-4853, 2011.
165. B. Hu, H. Yang, B. Dai, A. Tai, and P. Wang, "Nonintegrating lentiviral vectors can effectively deliver ovalbumin antigen for induction of antitumor immunity, " Human Gene Therapy, vol. 20, no. 12, pp. 1652-1664, 2009.
166. A. Kretz-Rommel, F. Qin, N. Dakappagari et al., "In vivo targeting of antigens to human dendritic cells through DCSIGN elicits stimulatory immune responses and inhibits tumor growth in grafted mouse models, " Journal of Immunotherapy, vol. 30, no. 7, pp. 715-726, 2007.
167. J. M. Odegard, B. Kelley-Clarke, S. U. Tareen et al., "Virological and preclinical characterization of a dendritic cell targeting, integration-deficient lentiviral vector for cancer immunotherapy, " Journal of Immunotherapy, vol. 38, no. 2, pp. 41-53, 2015.
168. S. U. Tareen, B. Kelley-Clarke, C. J. Nicolai et al., "Design of a novel integration-deficient lentivector technology that incorporates genetic and posttranslational elements to target human dendritic cells, " Molecular Therapy, vol. 22, no. 3, pp. 575-587, 2014.
169. Y. Delneste, G. Magistrelli, J.-F. Gauchat et al., "Involvement of LOX-1 in dendritic cell-mediated antigen cross-presentation, " Immunity, vol. 17, no. 3, pp. 353-362, 2002.
170. G. Picco, R. Beatson, J. Taylor-Papadimitriou, and J. M. Burchell, "Targeting DNGR-1 (CLEC9A) with antibody/MUC1 peptide conjugates as a vaccine for carcinomas, " European Journal of Immunology, vol. 44, no. 7, pp. 1947-1955, 2014.
171. K. Neubert, C. H. K. Lehmann, L. Heger et al., "Antigen delivery to CD11c+CD8? dendritic cells induces protective immune responses against experimental melanoma in mice in vivo, " Journal of Immunology, vol. 192, no. 12, pp. 5830-5838, 2014.
172. T. Akazawa, T. Ohashi, H. Nakajima et al., "Development of a dendritic cell-targeting lipopeptide as an immunoadjuvant that inhibits tumor growth without inducing local inflammation, " International Journal of Cancer, vol. 135, no. 12, pp. 2847-2856, 2014.
173. A. Faham and J. G. Altin, "Ag-bearing liposomes engrafted with peptides that interact with CD11c/CD18 induce potent Ag-specific and antitumor immunity, " International Journal of Cancer, vol. 129, no. 6, pp. 1391-1403, 2011.
174. X. Préville, D. Ladant, B. Timmerman, and C. Leclerc, "Eradication of established tumors by vaccination with recombinant Bordetella pertussis adenylate cyclase carrying the human papillomavirus 16 E7 oncoprotein, " Cancer Research, vol. 65,no. 2, pp. 641-649, 2005.
175. S. N. Furlan, R. Mandraju, T. Brewer et al., "Enhancement of anti-tumor CD8 immunity by IgG1-mediated targeting of Fc receptors, " mAbs, vol. 6, no. 1, pp. 108-118, 2014.
176. I. G. Zizzari, F. Veglia, F. Taurino et al., "HER2-based recombinant immunogen to target DCs through Fc γRs for cancer immunotherapy, " Journal of Molecular Medicine, vol. 89, no. 12, pp. 1231-1240, 2011.
177. P. Daftarian, A. E. Kaifer, W. Li et al., "Peptide-conjugated PAMAM dendrimer as a universal DNA vaccine platform to target antigen-presenting cells, " Cancer Research, vol. 71, no. 24, pp. 7452-7462, 2011.
178. A. Ageichik, C. J. Buchholz, and M. K. Collins, "Lentiviral vectors targeted to MHC II are effective in immunization, " Human GeneTherapy, vol. 22, no. 10, pp. 1249-1254, 2011.
179. F. Gennari, L. Lopes, E. Verhoeyen, W. Marasco, and M. K. Collins, "Single-chain antibodies that target lentiviral vectors to MHC class II on antigen-presenting cells, " Human Gene Therapy, vol. 20, no. 6, pp. 554-562, 2009.
180. A. B. Fredriksen, I. Sandlie, and B. Bogen, "Targeted DNA vaccines for enhanced induction of idiotype-specific B and T cells, " Frontiers in Oncology, vol. 2, article 154, 2012.
181. M. Froyland, P. A. Ruffini, K. M. Thompson, T. Gedde-Dahl, A. B. Fredriksen, and B. Bogen, "Targeted idiotype-fusion DNA vaccines for human multiple myeloma: preclinical testing, " European Journal of Haematology, vol. 86, no. 5, pp. 385-395, 2011.
182. J. Loschko, A. Schlitzer, D. Dudziak et al., "Antigen delivery to plasmacytoid dendritic cells via BST2 induces protective T cellmediated immunity, " The Journal of Immunology, vol. 186, no. 12, pp. 6718-6725, 2011.
183. D. Muraoka, N. Harada, T. Hayashi et al., "Nanogel-based immunologically stealth vaccine targets macrophages in the medulla of lymph node and induces potent antitumor immunity, " ACS Nano, vol. 8, no. 9, pp. 9209-9218, 2014.
184. L. M. Wood and Y. Paterson, "Attenuated Listeria monocytogenes: a powerful and versatile vector for the future of tumor immunotherapy, " Frontiers in Cellular and Infection Microbiology, vol. 4, article 51, 2014.
185. C. Perez-Shibayama, C. Gil-Cruz, M. Nussbacher et al., "Dendritic cell-specific delivery of flt3l by coronavirus vectors secures induction of therapeutic antitumor immunity, " PLoS ONE, vol. 8, no. 11, Article ID e81442, 2013.
186. L. Cervantes-Barragan, R. Zust, R. Maier et al., "Dendritic cell-specific antigen delivery by coronavirus vaccine vectors induces long-lasting protective antiviral and antitumor immunity, " mBio, vol. 1, no. 4, 2010.
187. P. Duewell, U. Kisser, K. Heckelsmiller et al., "ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cells, " Journal of Immunology, vol. 187, no. 1, pp. 55-63, 2011.
188. R. A. Rosalia, L. J. Cruz, S. van Duikeren et al., "CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses, " Biomaterials, vol. 40, pp. 88-97, 2015.
189. B. J. Williams, S. Bhatia, L. K. Adams et al., "Dendritic cell based PSMAimmunotherapy for prostate cancer using a CD40- targeted adenovirus vector, " PLoS ONE, vol. 7, no. 10, Article ID e46981, 2012.
190. B. N. Hangalapura, D. Oosterhoff, J. de Groot et al., "Potent antitumor immunity generated by a CD40-targeted adenoviral vaccine, " Cancer Research, vol. 71, no. 17, pp. 5827-5837, 2011.
191. B. N. Hangalapura, D. Oosterhoff, S. Aggarwal et al., "Selective transduction of dendritic cells in human lymph nodes and superior induction of high-avidity melanoma-reactive cytotoxic T cells by a CD40-targeted adenovirus, " Journal of Immunotherapy, vol. 33, no. 7, pp. 706-715, 2010.
192. U. E. Burkhardt, A. Sloots, V. Jakobi et al., "IL-15 augments antitumoral activity of an ErbB2/HER2 cancer vaccine targeted to professional antigen-presenting cells, " Cancer Immunology, Immunotherapy, vol. 61, no. 9, pp. 1473-1484, 2012.
193. H. Hemmi, N. Zaidi, B. Wang et al., "Treml4, an Ig superfamily member, mediates presentation of several antigens to T cells in vivo, including protective immunity to HER2 protein, " The Journal of Immunology, vol. 188, no. 3, pp. 1147-1155, 2012.
194. H. J. Cho, K. Takabayashi, P.-M. Cheng et al., "Immunostimulatory DNA-based vaccines induce cytotoxic lymphocyte activity by a T-helper cell-independent mechanism, " Nature Biotechnology, vol. 18, no. 5, pp. 509-514, 2000.
195. D. C. Jackson, F. L. Yuk, T. Le et al., "A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses, " Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 43, pp. 15440-15445, 2004.
196. A. K. Panda, "Induction of anti-tumor immunity and T-cell responses using nanodelivery systems engrafting TLR-5 ligand, " Expert Review of Vaccines, vol. 10, no. 2, pp. 155-157, 2011.
197. C. Mansilla, P. Berraondo, M. Durantez et al., "Eradication of large tumors expressing human papillomavirus E7 protein by therapeutic vaccination with E7 fused to the extra domain a from fibronectin, " International Journal of Cancer, vol. 131, no. 3, pp. 641-651, 2012.
198. F. Aranda, D. Llopiz, N. Diaz-Valdes et al., "Adjuvant combination and antigen targeting as a strategy to induce polyfunctional and high-avidity T-cell responses against poorly immunogenic tumors, " Cancer Research, vol. 71, no. 9, pp. 3214-3224, 2011.
199. A. Biragyn, K. Tani, M. C. Grimm, S. Weeks, and L. W. Kwak, "Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity, " Nature Biotechnology, vol. 17, no. 3, pp. 253-258, 1999.
200. E. Hartung, M. Becker, A. Bachem et al., "Induction of potent CD8 T cell cytotoxicity by specific targeting of antigen to crosspresenting dendritic cells in vivo via murine or human XCR1, " The Journal of Immunology, vol. 194, no. 3, pp. 1069-1079, 2015.